Article
Tazemetostat for relapsed/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study.
International journal of hematology - 1 Nov 2024
Izutsu Koji, Ando Kiyoshi, Nishikori Momoko, Shibayama Hirohiko, Goto Hideki, Kuroda Junya, Kato Koji, Imaizumi Yoshitaka, Nosaka Kisato, Sakai Rika, Abe Maho, Hojo Seiichiro, Nakanishi Tadashi, Rai Shinya
Abstract excerpt
Previously, we reported the efficacy and safety of tazemetostat in Japanese patients with relapsed/refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) harboring the EZH2 mutation in a multicenter, open-label, phase II study. Here, we present a follow-up analysis of tazemetostat at a long-term median follow-up of 35.0 months. Twenty patients were enrolled: 17 in the FL cohort and three in...
Topics
Join the communities discussing this publication.